In Hospital Supply, Signs of an M&A Renaissance?
Cardinal Health's acquisition of IV-pump specialist Alaris Medical Systems certainly came as no surprise. The company had been reportedly on the blocks for years. But the fact that Alaris fetched few takers was, certainly on some level, a reflection of the depressed prospects for hospital supply companies and, in turn, for M&A activity. Joining forces with Cardinal brings Alaris into the broader context of a bundled offering, and in the process, also reaffirms the value inherent in today's hospital supply marketplace. Teleflex's acquisition of Hudson Respiratory Care for $460 million marks a potentially more interesting deal. Teleflex officials have been looking for years for new properties to acquire, as part of a broader effort to build up and around their core businesses in wound closure and surgical instruments. The two deals taken together--Cardinal's acquisition of Alaris and Teleflex's of Hudson--suggest that deal-making in hospital supply is far from dead and may, in the future, be done from a business-building, rather than a business-fleeing posture.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.